Celltrion reports early results for four-action obesity drug

Celltrion has shared the first preclinical results for an obesity drug designed to act on four hormones at once.

The company tested the experimental treatment in mice.

The drug produced more weight loss than Celltrion’s three-action obesity drug candidate in the study.

It also caused a lower rate of loss in lean mass, the weight of the body excluding fat.

The findings are from animal testing, not trials in people, so they do not show how well the drug will work in humans.

Celltrion plans to begin human trials next year.

The results offer an early comparison, but the treatment’s effects in people remain to be tested.